menu
    • menu
    [{"orgOrder":0,"company":"Menarini","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Tagraxofusp","moa":"Interleukin-3 receptor subunit alpha | Elongation factor 2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Menarini","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Menarini \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Menarini \/ Inapplicable"},{"orgOrder":0,"company":"Menarini","sponsor":"Nippon Shinyaku","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Tagraxofusp","moa":"Interleukin-3 receptor subunit alpha | Elongation factor 2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Menarini","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Menarini \/ Nippon Shinyaku","highestDevelopmentStatusID":"15","companyTruncated":"Menarini \/ Nippon Shinyaku"},{"orgOrder":0,"company":"Nippon Shinyaku","sponsor":"Menarini","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"JAPAN","productType":"Protein","year":"2021","type":"Licensing Agreement","leadProduct":"Tagraxofusp","moa":"Interleukin-3 receptor subunit alpha | Elongation factor 2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Nippon Shinyaku","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Nippon Shinyaku \/ Menarini","highestDevelopmentStatusID":"15","companyTruncated":"Nippon Shinyaku \/ Menarini"},{"orgOrder":0,"company":"Stemline Therapeutics","sponsor":"Menarini","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Acquisition","leadProduct":"Tagraxofusp","moa":"Interleukin-3 receptor subunit alpha | Elongation factor 2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Stemline Therapeutics","amount2":0.68000000000000005,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.68000000000000005,"dosageForm":"Intravenous Injection","sponsorNew":"Stemline Therapeutics \/ Menarini","highestDevelopmentStatusID":"15","companyTruncated":"Stemline Therapeutics \/ Menarini"},{"orgOrder":0,"company":"Stemline Therapeutics","sponsor":"Menarini","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Acquisition","leadProduct":"Tagraxofusp","moa":"Interleukin-3 receptor subunit alpha | Elongation factor 2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Stemline Therapeutics","amount2":0.68000000000000005,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.68000000000000005,"dosageForm":"Intravenous Injection","sponsorNew":"Stemline Therapeutics \/ Menarini","highestDevelopmentStatusID":"15","companyTruncated":"Stemline Therapeutics \/ Menarini"},{"orgOrder":0,"company":"Joshua Zeidner","sponsor":"Stemline Therapeutics | University of North Carolina, Chapel Hill","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Tagraxofusp","moa":"Interleukin-3 receptor subunit alpha | Elongation factor 2","graph1":"Oncology","graph2":"Phase II","graph3":"Joshua Zeidner","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Joshua Zeidner \/ Stemline Therapeutics | University of North Carolina, Chapel Hill","highestDevelopmentStatusID":"8","companyTruncated":"Joshua Zeidner \/ Stemline Therapeutics | University of North Carolina, Chapel Hill"},{"orgOrder":0,"company":"Stemline Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Tagraxofusp","moa":"Interleukin-3 receptor subunit alpha | Elongation factor 2","graph1":"Oncology","graph2":"Phase II","graph3":"Stemline Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Stemline Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Stemline Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Stanford University","sponsor":"Stemline Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Tagraxofusp","moa":"Interleukin-3 receptor subunit alpha | Elongation factor 2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Stanford University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Stanford University \/ Stemline Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Stanford University \/ Stemline Therapeutics"},{"orgOrder":0,"company":"Stemline Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Tagraxofusp","moa":"Interleukin-3 receptor subunit alpha | Elongation factor 2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Stemline Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Stemline Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Stemline Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TACL Consortium","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Tagraxofusp","moa":"Interleukin-3 receptor subunit alpha | Elongation factor 2","graph1":"Oncology","graph2":"Phase I","graph3":"TACL Consortium","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TACL Consortium \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"TACL Consortium \/ Inapplicable"},{"orgOrder":0,"company":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins","sponsor":"Stemline Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Tagraxofusp","moa":"Interleukin-3 receptor subunit alpha | Elongation factor 2","graph1":"Oncology","graph2":"Phase I","graph3":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins \/ Stemline Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins \/ Stemline Therapeutics"},{"orgOrder":0,"company":"Stemline Therapeutics","sponsor":"Jacqueline Garcia | Break Through Cancer Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Tagraxofusp","moa":"Interleukin-3 receptor subunit alpha | Elongation factor 2","graph1":"Oncology","graph2":"Phase II","graph3":"Stemline Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Stemline Therapeutics \/ Jacqueline Garcia | Break Through Cancer Foundation","highestDevelopmentStatusID":"8","companyTruncated":"Stemline Therapeutics \/ Jacqueline Garcia | Break Through Cancer Foundation"}]

    Find Clinical Drug Pipeline Developments & Deals for Tagraxofusp

    Menu

    Tagraxofusp

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Stemline Therapeutics

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed

                            Stemline Therapeutics

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tagraxofusp

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Jacqueline Garcia | Break Through Cancer Foundation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Tagraxofusp + Azacitidine + Venetoclax Safety & Efficacy In MRD AML (Phase 1/2)

                            Details : Tagraxofusp is a Protein drug candidate, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of Leukemia, Myeloid, Acute.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            August 29, 2025

                            Lead Product(s) : Tagraxofusp

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Jacqueline Garcia | Break Through Cancer Foundation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Stanford University

                            Country arrow
                            ChemOutsourcing
                            Not Confirmed

                            Stanford University

                            Country arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tagraxofusp

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Stemline Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Tagraxofusp and Low-Intensity Chemotherapy for CD123-Positive Relapsed or Refractory AML

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            August 19, 2024

                            Lead Product(s) : Tagraxofusp

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Stemline Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Stemline Therapeutics

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed

                            Stemline Therapeutics

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tagraxofusp

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute My...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            June 13, 2024

                            Lead Product(s) : Tagraxofusp

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Menarini

                            Italy arrow
                            ChemOutsourcing
                            Not Confirmed

                            Menarini

                            Italy arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tagraxofusp

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Nippon Shinyaku

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            The Menarini Group Announces ELZONRIS® (Tagraxofusp) Designated as an Orphan Drug for BPDCN by Japanese Minis...

                            Details : ELZONRIS® (tagraxofusp), a recombinant protein is the only approved treatment for patients with blastic plasmacytoid dendritic cell neoplasm, and the first and only approved CD123-targeted therapy, in both the United States and Europe.

                            Product Name : Elzonris

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            August 30, 2023

                            Lead Product(s) : Tagraxofusp

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Nippon Shinyaku

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins

                            Country arrow
                            ChemOutsourcing
                            Not Confirmed

                            Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins

                            Country arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tagraxofusp

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Stemline Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Tagraxofusp-erzs, an IL-3 Diphtheria Fusion Protein, in Combination With Gemtuzumab Ozogamicin in Patients Wit...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            February 08, 2023

                            Lead Product(s) : Tagraxofusp

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Stemline Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            TACL Consortium

                            Country arrow
                            ChemOutsourcing
                            Not Confirmed

                            TACL Consortium

                            Country arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tagraxofusp

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            July 27, 2022

                            Lead Product(s) : Tagraxofusp

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Joshua Zeidner

                            Country arrow
                            ChemOutsourcing
                            Not Confirmed

                            Joshua Zeidner

                            Country arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tagraxofusp

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Stemline Therapeutics | University of North Carolina, Chapel Hill

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Tagraxofusp and Azaxitadine With or Without Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating ...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            July 01, 2022

                            Lead Product(s) : Tagraxofusp

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Stemline Therapeutics | University of North Carolina, Chapel Hill

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Nippon Shinyaku

                            Japan arrow
                            ChemOutsourcing
                            Not Confirmed

                            Nippon Shinyaku

                            Japan arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tagraxofusp

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Menarini

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Menarini Group and Nippon Shinyaku Enter into an Exclusive License Agreement to Develop and Commercialize ELZO...

                            Details : ELZONRIS (tagraxofusp) is the first approved treatment for patients with BPDCN, and the first approved CD123-targeted therapy, in both the United States and Europe. Elzonris was originally developed by Stemline Therapeutics, now part of the Menarini Grou...

                            Product Name : Elzonris

                            Product Type : Protein

                            Upfront Cash : Undisclosed

                            March 29, 2021

                            Lead Product(s) : Tagraxofusp

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Menarini

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Menarini

                            Italy arrow
                            ChemOutsourcing
                            Not Confirmed

                            Menarini

                            Italy arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tagraxofusp

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Menarini Receives European Commission Approval of ELZONRIS, for the Treatment of Blastic Plasmacytoid Dendriti...

                            Details : ELZONRIS is the first approved treatment for patients with BPDCN, and the first approved CD123-targeted therapy, in Europe. Approval is based on the results of the largest prospective clinical trial ever conducted in patients with treatment-naïve or pre...

                            Product Name : Elzonris

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            January 21, 2021

                            Lead Product(s) : Tagraxofusp

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Stemline Therapeutics

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed

                            Stemline Therapeutics

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tagraxofusp

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Menarini

                            Deal Size : $677.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Menarini Group Completes Acquisition of Stemline Therapeutics

                            Details : Acquisition establishes Menarini’s presence in the U.S. biopharmaceutical oncology market. Menarini will support further development of Stemline’s ELZONRIS and enable global expansion by leveraging its commercial infrastructure in Europe and other ex...

                            Product Name : Elzonris

                            Product Type : Protein

                            Upfront Cash : $677.0 million

                            October 06, 2020

                            Lead Product(s) : Tagraxofusp

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Menarini

                            Deal Size : $677.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth